TSBX צמיחת רווח נקי למניה השנה Turnstone Biologics

Turnstone Biologics (TSBX) plans to generate revenue through the implementation of innovative TIL cell therapy against solid tumors. The annual earnings per share volatility metric helps avoid speculative peaks, with the current parameter equal to 0.00. Growth is driven by unique cell selection and TIDAL-01 tests. Future revenues are protected by patents, guaranteeing the company high pricing power in immuno-oncology.
פילוחים אנליטיים ודוחות נתונים של חברת turnstonebio.com (TSBX)

This indicator measures the net income per share dynamics over twelve months, reflecting the efficiency of the business capitalization. For Turnstone Biologics (TSBX), the annual EPS percentage change depends not on market cycles, but on progress in immuno-oncology and R&D success. Monitoring this metric allows an investor to recognize the degradation of fundamentals in a timely manner and protect capital from asset depreciation.